Study Researches Cancer's Hiding Spots

"In a study conducted on mice with lymphoma, scientists discovered cancer cells that escape chemotherapy by hiding in the thymus, an organ where immune cells mature. In the thymus, cancer cells are covered in growth factors that protect them from the drugs’ effects. These cells are likely the source of relapse tumors.

The researchers, led by Michael Hemann, MIT assistant professor of biology, plan to conduct more tests on mice to determine if certain arthritis drugs interfere with at least one of the protective growth factors. This drug, or one like it, used in combination with traditional chemotherapy, could offer a one-two punch that eliminates residual tumor cells and prevents cancer relapse, according to the researchers.

"Successful cancer therapy needs to involve a component that kills tumor cells as well as a component that blocks pro-survival signals," Hemann, who is a member of MIT's David H. Koch Institute for Integrative Cancer Research was quoted as saying. "Current cancer therapies fail to target this survival response."

In this study, the researchers treated the mice with lymphoma with doxorubicin, a drug commonly used to treat a wide range of cancers, including blood cancers. They found that during treatment, cells that line the blood vessels release cytokines- small proteins that influence immune responses and cell development."

Read More: http://www.redorbit.com/news/health/1942035/cancers_hiding_spots/index.html

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap